CC 220

Drug Profile

CC 220

Alternative Names: CC-220

Latest Information Update: 24 Jan 2017

Price : $50

At a glance

  • Originator Celgene Corporation
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action CRBN protein inhibitors; Immunomodulators; Transcription factor modulators; Ubiquitin protein ligase complex modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Systemic lupus erythematosus
  • Phase I/II Multiple myeloma
  • Discontinued Cutaneous lupus erythematosus; Haematological malignancies; Sarcoidosis; Systemic scleroderma

Most Recent Events

  • 03 Dec 2016 Pharmacodynamics and pharmacokinetics data from a preclinical study in Multiple myeloma presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016)
  • 01 Oct 2016 Phase-I/II clinical trials in Multiple myeloma (Combination therapy, Monotherapy, Second-line therapy or greater) in Spain, Italy, USA (PO) (NCT02773030)
  • 01 Sep 2016 Celgene Corporation completes a phase I pharmacokinetics trial in Healthy volunteers in USA (PO) (NCT02820935)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top